NCT06592625

Neoadjuvant SHR-A1811 Plus Adebrelimab in HR Negative/Low & HER2 Low Breast Cancer Patients

A Multicenter, Single-arm, Phase 2 Study of Neoadjuvant SHR-A1811 Plus Adebrelimab Injection for Early-stage or Locally Advanced HR Negative or Low Expression/HER2 Low Expression Breast Cancer

• Status: Not Yet Recruiting
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 60 (estimated)
• Sponsor: Suzhou Suncadia Biopharmaceuticals Co., Ltd. · Industry
• Sex: Female
• Age: 18 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

The study is being conducted to evaluate the preliminary efficacy, safety, and pharmacokinetic characteristics of the combination of SHR-A1811 with Adebrelimab Injection in treatment-naive patients with early-stage or locally advanced HR-negative or low expression, HER2 low expression breast cancer.

Conditions

• Untreated Early-stage or Locally Advanced Breast Cancer

Interventions

Type	Name	Description
DRUG	SHR-A1811	SHR-A1811
DRUG	Adebrelimab	Adebrelimab

Timeline

• Start date: 2024-09-20
• Primary completion: 2026-02-28
• Completion: 2026-02-28
• First posted: 2024-09-19
• Last updated: 2024-09-19

Locations

1 site across 1 country: China